At a glance
ClinicalIndex Comparison RecordN/ACompleted· 21 enrolled
Drug / intervention
Sculptra +1 moredevice
Likely dose
Not stated in record
Key inclusion· 4
- ✓Minimum shallow nasolabial fold contour deficiencies as assessed by wrinkle assessment scale (WAS)
- ✓Identical WAS scores on both nasolabial folds (symmetric baseline)
- ✓Able to provide informed consent
- ✓Agreement to undergo skin biopsies on nasolabial folds
Key exclusion· 4
- ✕Significant nasolabial fold asymmetry or different WAS scores between sides
- ✕Pregnant, planning pregnancy, or breastfeeding
- ✕History of allergy or hypersensitivity to treatment product ingredients
- ✕History of allergy or hypersensitivity to anesthetics or lidocaine
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Single-center, Prospective Biopsy Study Comparing a Poly L-lactic Acid Biostimulator and a Calcium Hydroxylapatite Semi-permanent Filler
In Brief
A clinical study evaluating Sculptra and Radiesse Plus for Gene Expression. Completed, enrolled 21 participants across 1 site.
Detailed Summary
To compare gene expression stimulated by a semi-permanent filler and a biostimulator via punch biopsy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGene Expression
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2023202420252026
Enrollment StartSep 2022
First PostedNov 2022
Primary CompletionJul 2023
Study CompletionNov 2023
TodayJul 2026
First PostedNov 17, 2022
Enrollment StartSep 28, 2022
Primary CompletionJul 25, 2023
Study CompletionNov 6, 2023
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 3.6 years ago
Interventions
Sculptradevice
Biostimulator
Radiesse Plusdevice
Semi-permanent filler